Emyria Receives positive screening results for MDMA-inspired analogues
- Emyria (EMD) receives positive screening results from its MDMA novel drug discovery program with the University of Western Australia (UWA)
- All 19 compounds sent from the third batch of compounds from the company’s MDMA analogue library successfully passed screening with Eurofins at the test concentrations
- Further, the tested compounds show no evidence of significant interactions with any enzymes or cell receptors associated with unwanted clinical side effects
- Based on the initial screening results, preclinical evaluations have commenced on a number of high priority compounds
- Shares in the company are up 11.8 per cent, trading at 28.5 cents at market close
